You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Number of patients who developed CMV episode(s) within 12 months of transplant according to donor (D) and recipient (R) CMV serology

From: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

Pre-transplant CMV serology Total number (%) Number (%) of patients who developed CMV episode(s)
0 1 ≥2
D−/R- 58 (28%) 55 (26.4%) 1 (0.5%) 2 (1.0%)
D−/R+ 59 (28.5%) 28 (13.5%) 19 (9.1%) 12 (5.8%)
D+/R- 20 (9.5%) 15 (7.2%) 4 (1.9%) 1 (0.5%)
D+/R+ 71 (34%) 40 (19.2%) 20 (9.6%) 11 (5.3%)
Total 208 (100%) 138 (66.4%) 44 (21.2%) 26 (12.5%)